Clinical and immune evolution in neurological/psychiatric patients during the COVID-19 pandemic;


Por: Toledo A., Gaona M.A., Delgadillo T., Arellano C.T., Padilla A., Bravo S., Alipi H., Toledo V., Del Rio Quiñones M.A., De la Cruz-Aguilera D.L., Aguirre-Cruz L., Fleury A.

Publicada: 1 ene 2025
Resumen:
Introduction: The COVID-19 pandemic has had a disastrous impact on the world's population. Its effects were mainly respiratory, but resulting neurological damage has also been described. In this context, we evaluated the effects of COVID-19 on the subjective perception of neurological and psychiatric symptoms in patients with pre-pandemic neuropsychiatric diseases, as well as the possible association between the evolution of these symptoms and immunological factors. Methods: A cohort of neurological/psychiatric patients with (n = 99) or without (n = 42) a history of COVID-19 was included. Inclusion took place 7 months after COVID-19 infection, and follow-up was performed 14 months after inclusion. At both assessments, included subjects were asked whether they considered their neurological/psychiatric symptoms to be stable, worsened or improved compared with the situation before COVID-19, or compared with the first assessment. A blood sample of all subjects was taken at both assessments to determine levels of several cytokines. Results: A worsening of neurological/psychiatric symptoms was reported by 36.9% of patients, when comparing the situation at follow-up with that prior to COVID-19. Comparing with controls, patients with history of COVID-19 had significantly higher levels of IL-6 and IFN-?, and patients with a history of symptomatic COVID-19 presented a significant higher level of IL-10. IFN-? was significantly associated with COVID-19 severity, and its decrease during follow-up was associated with improvement of neurological/psychiatric symptoms in neurological patients with a history of COVID-19, but not in control patients. Conclusions: More than 35% of included neuropsychiatric patients have reported worsening of symptoms after non-severe COVID-19. IFN-? seems to be a marker linked to COVID-19 pathogeny and its evaluation might be useful for monitoring affected patients. © 2025

Filiaciones:
Toledo A.:
 División de investigación, Facultad de Medicina, Universidad Nacional Autónoma de México (UNAM), circuito universitario s/n, México City, C.P. 04510, Mexico

 Unidad de Neuro Inflamación, Departamento de Medicina Genómica y Toxicología ambiental, Instituto de Investigaciones Biomédicas, UNAM/Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez (INNN-MVS), México City, C.P. 14269, Mexico

Gaona M.A.:
 Unidad de Neuro Inflamación, Departamento de Medicina Genómica y Toxicología ambiental, Instituto de Investigaciones Biomédicas, UNAM/Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez (INNN-MVS), México City, C.P. 14269, Mexico

Delgadillo T.:
 Unidad de Neuro Inflamación, Departamento de Medicina Genómica y Toxicología ambiental, Instituto de Investigaciones Biomédicas, UNAM/Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez (INNN-MVS), México City, C.P. 14269, Mexico

Arellano C.T.:
 Unidad de Neuro Inflamación, Departamento de Medicina Genómica y Toxicología ambiental, Instituto de Investigaciones Biomédicas, UNAM/Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez (INNN-MVS), México City, C.P. 14269, Mexico

Padilla A.:
 Unidad de Neuro Inflamación, Departamento de Medicina Genómica y Toxicología ambiental, Instituto de Investigaciones Biomédicas, UNAM/Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez (INNN-MVS), México City, C.P. 14269, Mexico

Bravo S.:
 Unidad de Neuro Inflamación, Departamento de Medicina Genómica y Toxicología ambiental, Instituto de Investigaciones Biomédicas, UNAM/Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez (INNN-MVS), México City, C.P. 14269, Mexico

Alipi H.:
 Unidad de Neuro Inflamación, Departamento de Medicina Genómica y Toxicología ambiental, Instituto de Investigaciones Biomédicas, UNAM/Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez (INNN-MVS), México City, C.P. 14269, Mexico

Toledo V.:
 Unidad de Neuro Inflamación, Departamento de Medicina Genómica y Toxicología ambiental, Instituto de Investigaciones Biomédicas, UNAM/Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez (INNN-MVS), México City, C.P. 14269, Mexico

Del Rio Quiñones M.A.:
 Subdirección de Consulta Externa, INNN-MVS, México City, C.P. 14269, Mexico

De la Cruz-Aguilera D.L.:
 Laboratorio de Neuroinmunoendocrinología, INNN-MVS, México City, C.P. 14269, Mexico

Aguirre-Cruz L.:
 Laboratorio de Neuroinmunoendocrinología, INNN-MVS, México City, C.P. 14269, Mexico

Fleury A.:
 Unidad de Neuro Inflamación, Departamento de Medicina Genómica y Toxicología ambiental, Instituto de Investigaciones Biomédicas, UNAM/Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez (INNN-MVS), México City, C.P. 14269, Mexico

 Consulta externa, INNN-MVS, México City, C.P. 14269, Mexico
ISSN: 26670496
Editorial
Ediciones Doyma, S.L.
Tipo de documento: Article
Volumen: 5 Número: 2
Páginas: